Log in

NASDAQ:CRVS - Corvus Pharmaceuticals Stock Price, Forecast & News

$5.70
+0.32 (+5.95 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.31
Now: $5.70▼
$5.89
50-Day Range
$3.02
MA: $4.39▼
$5.70
52-Week Range
$2.53
Now: $5.70▼
$8.10
Volume227,510 shs
Average Volume163,284 shs
Market Capitalization$167.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
Previous Symbol
CUSIPN/A
CIK1626971
Webhttp://www.corvuspharma.com/
Phone650-900-4520

Debt

Debt-to-Equity Ratio0.03
Current Ratio9.23
Quick Ratio9.23

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.77 per share
Price / Book1.51

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-46,940,000.00
Net MarginsN/A
Return on Equity-48.42%
Return on Assets-43.31%

Miscellaneous

Employees49
Outstanding Shares29,405,000
Market Cap$167.61 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:CRVS Rates by TradingView

A Rare Upcoming Change to Bitcoin Could Yield Profits of 2,752% (Ad)


Free Report: In a few months the Bitcoin network will undergo a major change that will make it more scarce than ever before. Historically, this event has been correlated to a major price increase.

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) posted its earnings results on Tuesday, October, 29th. The company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.05. View Corvus Pharmaceuticals' Earnings History.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Corvus Pharmaceuticals.

What price target have analysts set for CRVS?

3 Wall Street analysts have issued 1 year price objectives for Corvus Pharmaceuticals' stock. Their forecasts range from $6.00 to $11.00. On average, they expect Corvus Pharmaceuticals' share price to reach $8.00 in the next year. This suggests a possible upside of 40.4% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.

What is the consensus analysts' recommendation for Corvus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.

What are Wall Street analysts saying about Corvus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Corvus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. " (12/31/2019)
  • 2. Mizuho analysts commented, "We initiate coverage of CRVS at $7 PT. We like the adenosine (ADO)-A2AR pathway and believe there is promise in combination therapy. The shares have struggled due to, in our view, underwhelming ciforadenant monotherapy data but we see CPI-006 as the opportunity to reset expectations." (9/11/2019)

Has Corvus Pharmaceuticals been receiving favorable news coverage?

News headlines about CRVS stock have been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Corvus Pharmaceuticals.

Who are some of Corvus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corvus Pharmaceuticals own?

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
  • Mr. Leiv Lea, Chief Financial Officer (Age 65)
  • Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
  • Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
  • Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $5.70.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $167.61 million. Corvus Pharmaceuticals employs 49 workers across the globe.View Additional Information About Corvus Pharmaceuticals.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is http://www.corvuspharma.com/.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]


MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Technical Indicators - What is a Golden Cross?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel